Teyi Pharmaceutical Group Co Ltd (002728) - Net Assets
Based on the latest financial reports, Teyi Pharmaceutical Group Co Ltd (002728) has net assets worth CN¥1.80 Billion CNY (≈ $263.83 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.22 Billion ≈ $324.94 Million USD) and total liabilities (CN¥417.67 Million ≈ $61.12 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Teyi Pharmaceutical Group Co Ltd asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.80 Billion |
| % of Total Assets | 81.19% |
| Annual Growth Rate | 20.84% |
| 5-Year Change | 63.35% |
| 10-Year Change | 119.44% |
| Growth Volatility | 29.65 |
Teyi Pharmaceutical Group Co Ltd - Net Assets Trend (2009–2024)
This chart illustrates how Teyi Pharmaceutical Group Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Teyi Pharmaceutical Group Co Ltd for the complete picture of this company's asset base.
Annual Net Assets for Teyi Pharmaceutical Group Co Ltd (2009–2024)
The table below shows the annual net assets of Teyi Pharmaceutical Group Co Ltd from 2009 to 2024. For live valuation and market cap data, see 002728 market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.76 Billion ≈ $258.27 Million |
-12.22% |
| 2023-12-31 | CN¥2.01 Billion ≈ $294.23 Million |
+43.30% |
| 2022-12-31 | CN¥1.40 Billion ≈ $205.32 Million |
+11.21% |
| 2021-12-31 | CN¥1.26 Billion ≈ $184.62 Million |
+16.78% |
| 2020-12-31 | CN¥1.08 Billion ≈ $158.10 Million |
-6.30% |
| 2019-12-31 | CN¥1.15 Billion ≈ $168.73 Million |
+3.76% |
| 2018-12-31 | CN¥1.11 Billion ≈ $162.60 Million |
+6.56% |
| 2017-12-31 | CN¥1.04 Billion ≈ $152.60 Million |
+17.63% |
| 2016-12-31 | CN¥886.57 Million ≈ $129.73 Million |
+10.23% |
| 2015-12-31 | CN¥804.30 Million ≈ $117.69 Million |
+9.33% |
| 2014-12-31 | CN¥735.64 Million ≈ $107.65 Million |
+110.10% |
| 2013-12-31 | CN¥350.14 Million ≈ $51.24 Million |
+22.71% |
| 2012-12-31 | CN¥285.34 Million ≈ $41.75 Million |
+26.53% |
| 2011-12-31 | CN¥225.51 Million ≈ $33.00 Million |
+32.02% |
| 2010-12-31 | CN¥170.81 Million ≈ $25.00 Million |
+65.55% |
| 2009-12-31 | CN¥103.18 Million ≈ $15.10 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Teyi Pharmaceutical Group Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2202.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥353.49 Million | 20.03% |
| Common Stock | CN¥512.21 Million | 29.02% |
| Other Comprehensive Income | CN¥150.23 Million | 8.51% |
| Other Components | CN¥749.00 Million | 42.44% |
| Total Equity | CN¥1.76 Billion | 100.00% |
Teyi Pharmaceutical Group Co Ltd Competitors by Market Cap
The table below lists competitors of Teyi Pharmaceutical Group Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jiangsu Jinling Sports Equipment Co Ltd
SHE:300651
|
$745.54 Million |
|
Tian Jin Global Magnetic Card Co Ltd
SHG:600800
|
$745.57 Million |
|
Gujarat Narmada Valley Fertilizers and Chemicals Limited
NSE:GNFC
|
$745.77 Million |
|
Kri-Kri Milk Industry S.A
AT:KRI
|
$745.93 Million |
|
Zhejiang He Chuan Technology Corp. Ltd. A
SHG:688320
|
$745.37 Million |
|
B Communications Ltd
TA:BCOM
|
$745.08 Million |
|
COMSTOCK HLDG-A
F:CHO
|
$744.97 Million |
|
Shanghai Kinetic Medical Co
SHE:300326
|
$744.94 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Teyi Pharmaceutical Group Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,010,681,910 to 1,764,933,238, a change of -245,748,672 (-12.2%).
- Net income of 20,495,003 contributed positively to equity growth.
- Dividend payments of 182,307,116 reduced retained earnings.
- Share repurchases of 93,856,250 reduced equity.
- Other comprehensive income increased equity by 143,919,747.
- Other factors decreased equity by 134,000,056.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥20.50 Million | +1.16% |
| Dividends Paid | CN¥182.31 Million | -10.33% |
| Share Repurchases | CN¥93.86 Million | -5.32% |
| Other Comprehensive Income | CN¥143.92 Million | +8.15% |
| Other Changes | CN¥-134.00 Million | -7.59% |
| Total Change | CN¥- | -12.22% |
Book Value vs Market Value Analysis
This analysis compares Teyi Pharmaceutical Group Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.88x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 18.56x to 2.88x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | CN¥0.54 | CN¥9.93 | x |
| 2010-12-31 | CN¥0.84 | CN¥9.93 | x |
| 2011-12-31 | CN¥1.07 | CN¥9.93 | x |
| 2012-12-31 | CN¥1.36 | CN¥9.93 | x |
| 2013-12-31 | CN¥1.66 | CN¥9.93 | x |
| 2014-12-31 | CN¥3.08 | CN¥9.93 | x |
| 2015-12-31 | CN¥2.90 | CN¥9.93 | x |
| 2016-12-31 | CN¥3.14 | CN¥9.93 | x |
| 2017-12-31 | CN¥3.71 | CN¥9.93 | x |
| 2018-12-31 | CN¥3.98 | CN¥9.93 | x |
| 2019-12-31 | CN¥4.03 | CN¥9.93 | x |
| 2020-12-31 | CN¥6.52 | CN¥9.93 | x |
| 2021-12-31 | CN¥6.06 | CN¥9.93 | x |
| 2022-12-31 | CN¥4.50 | CN¥9.93 | x |
| 2023-12-31 | CN¥4.37 | CN¥9.93 | x |
| 2024-12-31 | CN¥3.44 | CN¥9.93 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Teyi Pharmaceutical Group Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.16%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.98%
- • Asset Turnover: 0.29x
- • Equity Multiplier: 1.36x
- Recent ROE (1.16%) is below the historical average (15.26%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | 23.36% | 11.92% | 1.07x | 1.84x | CN¥13.78 Million |
| 2010 | 28.09% | 19.13% | 0.99x | 1.48x | CN¥30.90 Million |
| 2011 | 30.91% | 22.84% | 1.08x | 1.26x | CN¥47.14 Million |
| 2012 | 27.54% | 23.06% | 0.88x | 1.36x | CN¥50.04 Million |
| 2013 | 23.01% | 23.50% | 0.76x | 1.30x | CN¥45.54 Million |
| 2014 | 10.90% | 23.26% | 0.42x | 1.12x | CN¥6.63 Million |
| 2015 | 10.08% | 15.70% | 0.32x | 1.99x | CN¥675.46K |
| 2016 | 10.69% | 14.45% | 0.41x | 1.81x | CN¥6.12 Million |
| 2017 | 10.20% | 15.48% | 0.36x | 1.85x | CN¥2.06 Million |
| 2018 | 14.00% | 17.58% | 0.43x | 1.86x | CN¥44.43 Million |
| 2019 | 14.89% | 18.64% | 0.41x | 1.96x | CN¥56.41 Million |
| 2020 | 4.06% | 6.93% | 0.28x | 2.09x | CN¥-64.23 Million |
| 2021 | 10.06% | 16.74% | 0.37x | 1.64x | CN¥748.41K |
| 2022 | 12.70% | 20.10% | 0.35x | 1.81x | CN¥37.89 Million |
| 2023 | 12.59% | 23.72% | 0.42x | 1.25x | CN¥52.11 Million |
| 2024 | 1.16% | 2.98% | 0.29x | 1.36x | CN¥-156.00 Million |
Industry Comparison
This section compares Teyi Pharmaceutical Group Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $1,347,197,696
- Average return on equity (ROE) among peers: 4.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Teyi Pharmaceutical Group Co Ltd (002728) | CN¥1.80 Billion | 23.36% | 0.23x | $745.43 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $2.84 Billion | -41.97% | 9.13x | $1.22 Billion |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $638.89 Million | 0.88% | 0.70x | $438.59 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $1.05 Billion | 10.46% | 0.19x | $5.18 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $1.07 Billion | 3.83% | 0.46x | $2.81 Billion |
| Wedge Industrial Co Ltd (000534) | $1.29 Billion | 11.69% | 1.47x | $2.95 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $13.85 Billion |
| Hainan Haiyao Co Ltd (000566) | $5.08 Billion | 1.71% | 1.08x | $949.23 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $141.91 Million | 11.01% | 0.32x | $391.07 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $994.58 Million | 2.01% | 2.11x | $1.03 Billion |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $332.48 Million | 26.89% | 0.68x | $3.30 Billion |
About Teyi Pharmaceutical Group Co Ltd
Teyi Pharmaceutical Group Co.,Ltd engages in the research and development, production, and sale of Chinese patented medicines, pharmaceutical preparations, raw materials, and products in the People's Republic of China. The company provides cough and phlegm, kidney, anti-infection, cardiovascular and cerebrovascular, and digestive system drugs, as well as pediatrics, dermatology, tuberculosis, res… Read more